4.8 Article

Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species

Related references

Note: Only part of the references are listed.
Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

Article Multidisciplinary Sciences

Spike mutation D614G alters SARS-CoV-2 fitness

Jessica A. Plante et al.

Summary: The D614G substitution in the SARS-CoV-2 spike protein enhances viral replication and infectivity in human lung epithelial cells, primary airway tissues, and hamsters. This variant may increase transmission in the upper respiratory tract and doesn't seem to significantly reduce vaccine efficacy. Further research on therapeutic antibodies targeting the circulating G614 virus is recommended.

NATURE (2021)

Article Biochemistry & Molecular Biology

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

Erik Volz et al.

Summary: The study suggests a positive selection for the SARS-CoV-2 spike protein variant D614G in the UK, but no evidence of differences in COVID-19 mortality or clinical severity in patients infected with this variant. 614G is associated with higher viral load and younger age of patients compared to 614D.
Article Microbiology

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

Drew Weissman et al.

Summary: The D614G mutation in the spike protein of SARS-CoV-2 is not expected to hinder current vaccine development, as viruses with the G614 spike are more susceptible to neutralization, indicating that the mutation may not affect vaccine efficacy.

CELL HOST & MICROBE (2021)

Article Medicine, General & Internal

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19 A Randomized Clinical Trial

Robert L. Gottlieb et al.

Summary: The study showed that treatment with bamlanivimab and etesevimab was significantly associated with a reduction in SARS-CoV-2 viral load at day 11 in nonhospitalized patients with mild to moderate COVID-19, compared to placebo. However, bamlanivimab monotherapy did not show a significant reduction in viral load. Ongoing clinical trials will focus on assessing the clinical benefits of antispike neutralizing antibodies in COVID-19 patients.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

News Item Multidisciplinary Sciences

FAST-SPREADING COVID VARIANT CAN ELUDE IMMUNE RESPONSES

Ewen Callaway

NATURE (2021)

Article Medicine, General & Internal

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

D. M. Weinreich et al.

Summary: Recent data indicate that complications and death from Covid-19 may be related to high viral loads. In this trial involving nonhospitalized patients, a cocktail of two neutralizing monoclonal antibodies (REGN-COV2) reduced viral load, with a greater effect in patients with no immune response or high viral load at baseline. Safety outcomes were similar between REGN-COV2 dose groups and the placebo group.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Medicine, General & Internal

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen et al.

Summary: LY-CoV555, a neutralizing antibody, showed promising results in reducing viral load, improving symptoms, and lowering the risk of hospitalization among patients with mild or moderate Covid-19. While one of the doses appeared to accelerate the decline in viral load, others did not show significant effects by day 11.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

News Item Multidisciplinary Sciences

COVID-19 Fast-spreading UK virus variant raises alarms

Kai Kupferschmidt

SCIENCE (2021)

Article Multidisciplinary Sciences

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

Jiwan Ge et al.

Summary: The authors compare the crystal structures and investigate the neutralization mechanisms of three neutralizing antibodies against SARS-CoV-2 and find that one antibody, P2C-1F11, closely mimics binding of receptor ACE2 and displays the most potent neutralizing activity in vitro, as well as conferring protection against SARS-CoV-2 infection in Ad5-hACE2-sensitized mice.

NATURE COMMUNICATIONS (2021)

Article Microbiology

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Gabriele Cerutti et al.

Summary: Structural analysis revealed that seven potent NTD-directed neutralizing antibodies target a common surface on NTD, forming a single supersite different from the recognition pattern of RBD-directed antibodies.

CELL HOST & MICROBE (2021)

Editorial Material Medicine, General & Internal

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Ester C. Sabino et al.

LANCET (2021)

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Article Multidisciplinary Sciences

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Annette B. Vogel et al.

Summary: The two vaccine candidates, BNT162b1 and BNT162b2, developed contain modified messenger RNA encoding immunogens derived from the spike glycoprotein of SARS-CoV-2. They have shown promising immune responses in mice and rhesus macaques, with ongoing phase I trials in Germany and the USA and a global phase II/III trial for BNT162b2.

NATURE (2021)

Article Biochemistry & Molecular Biology

Sixteen novel lineages of SARS-CoV-2 in South Africa

Houriiyah Tegally et al.

Summary: The study identified 16 new lineages of SARS-CoV-2 in South Africa between March and August 2020, with unique mutations not found elsewhere. Three lineages (B.1.1.54, B.1.1.56, and C.1) dominated during the country's first wave, accounting for approximately 42% of all infections. The C.1 lineage, with 16 nucleotide mutations including the D614G spike protein change, became the most geographically widespread by August 2020. Genomic surveillance played a crucial role in identifying the 501Y.V2 variant in South Africa in December 2020.

NATURE MEDICINE (2021)

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Biochemistry & Molecular Biology

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Naveenchandra Suryadevara et al.

Summary: The study found that a subset of human monoclonal antibodies derived from convalescent SARS-CoV-2 patients possess neutralizing activity, with two antibodies capable of inhibiting infection. Mechanistic studies revealed these antibodies neutralize in part by inhibiting post-attachment steps in the infection cycle.
Article Biochemistry & Molecular Biology

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Matthew McCallum et al.

Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.
Article Biochemistry & Molecular Biology

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Markus Hoffmann et al.

Summary: The emerging SARS-CoV-2 variants may exhibit resistance to existing neutralizing antibodies and treatments, which could have significant implications for pandemic containment efforts.
Article Biochemistry & Molecular Biology

Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants

Charlie Laffeber et al.

Summary: Different mutations in new variants of SARS-CoV-2 have varying effects on receptor binding affinity, viral transmission, and immune evasion, highlighting the importance of global viral genome surveillance and functional characterization.

JOURNAL OF MOLECULAR BIOLOGY (2021)

Letter Infectious Diseases

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2

Baoying Huang et al.

LANCET MICROBE (2021)

Letter Immunology

Imported SARS-CoV-2 Variant P.1 in Traveler Returning from Brazil to Italy

Fabrizio Maggi et al.

Summary: This case is an imported one where an asymptomatic traveler arrived in Italy and tested positive for the SARS-CoV-2 variant P.1 after traveling indirectly from Brazil, highlighting the risk of introducing SARS-CoV-2 variants through indirect flights and the importance of continued surveillance for SARS-CoV-2.

EMERGING INFECTIOUS DISEASES (2021)

Letter Immunology

Novel SARS-CoV-2 Variant in Travelers from Brazil to Japan

Takahisa Fujino et al.

Summary: Different variants of SARS-CoV-2 with higher transmission potential have been emerging globally, including one found in travelers from Brazil to Japan in January 2021, which carries an additional set of mutations.

EMERGING INFECTIOUS DISEASES (2021)

Article Multidisciplinary Sciences

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans

Bas B. Oude Munnink et al.

Summary: Animal experiments have shown that various animals can be infected by SARS-CoV-2, with evidence of animal-to-human transmission within mink farms. Investigation into mink farm outbreaks revealed that the virus was initially introduced by humans and has since evolved, causing transmission between mink farms. Despite enhanced biosecurity measures and culling, transmission occurred between farms in three large clusters with unknown modes of transmission, resulting in a high percentage of infections among mink farm residents and employees.

SCIENCE (2021)

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Article Multidisciplinary Sciences

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Bin Ju et al.

NATURE (2020)

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Article Biochemistry & Molecular Biology

Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant

Leonid Yurkovetskiy et al.

Article Multidisciplinary Sciences

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani et al.

NATURE (2020)

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Article Multidisciplinary Sciences

Potently neutralizing and protective human antibodies against SARS-CoV-2

Seth J. Zost et al.

NATURE (2020)

Article Medicine, General & Internal

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Kizzmekia S. Corbett et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Article Multidisciplinary Sciences

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Johanna Hansen et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

Structural basis of a shared antibody response to SARS-CoV-2

Meng Yuan et al.

SCIENCE (2020)

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

Article Multidisciplinary Sciences

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

Shipo Wu et al.

NATURE COMMUNICATIONS (2020)

Article Multidisciplinary Sciences

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Yixuan J. Hou et al.

SCIENCE (2020)

Article Biochemical Research Methods

PyMod 2.0: improvements in protein sequence-structure analysis and homology modeling within PyMOL

Giacomo Janson et al.

BIOINFORMATICS (2017)

Article Biochemical Research Methods

Features and development of Coot

P. Emsley et al.

ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY (2010)

Article Biochemical Research Methods

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Paul D. Adams et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)

Article Chemistry, Multidisciplinary

Phaser crystallographic software

Airlie J. McCoy et al.

JOURNAL OF APPLIED CRYSTALLOGRAPHY (2007)

Article Chemistry, Multidisciplinary

UCSF chimera - A visualization system for exploratory research and analysis

EF Pettersen et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)